Correlation Between Acumen Pharmaceuticals and Evolutionary Genomics

Can any of the company-specific risk be diversified away by investing in both Acumen Pharmaceuticals and Evolutionary Genomics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acumen Pharmaceuticals and Evolutionary Genomics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Acumen Pharmaceuticals and Evolutionary Genomics, you can compare the effects of market volatilities on Acumen Pharmaceuticals and Evolutionary Genomics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acumen Pharmaceuticals with a short position of Evolutionary Genomics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acumen Pharmaceuticals and Evolutionary Genomics.

Diversification Opportunities for Acumen Pharmaceuticals and Evolutionary Genomics

0.0

Correlation Coefficient

Acumen Pharmaceuticals  Evolutionary Genomics

Pay attention - limited upside

The 3 months correlation between Acumen and Evolutionary is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Acumen Pharmaceuticals and Evolutionary Genomics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Evolutionary Genomics and Acumen Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acumen Pharmaceuticals are associated (or correlated) with Evolutionary Genomics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Evolutionary Genomics has no effect on the direction of Acumen Pharmaceuticals i.e., Acumen Pharmaceuticals and Evolutionary Genomics go up and down completely randomly.

Pair Corralation between Acumen Pharmaceuticals and Evolutionary Genomics

If you would invest  101.00  in Acumen Pharmaceuticals on May 15, 2025 and sell it today you would earn a total of  25.00  from holding Acumen Pharmaceuticals or generate 24.75% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Flat
Strength	Insignificant
Accuracy	98.41%
Values	Daily Returns

Acumen Pharmaceuticals  vs.  Evolutionary Genomics

Acumen Pharmaceuticals

Risk-Adjusted Performance

Fair

Compared to the overall equity markets, risk-adjusted returns on investments in Acumen Pharmaceuticals are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Acumen Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Evolutionary Genomics

Risk-Adjusted Performance

Weakest

Over the last 90 days Evolutionary Genomics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Evolutionary Genomics is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors.

Pair Trading with Acumen Pharmaceuticals and Evolutionary Genomics

The main advantage of trading using opposite Acumen Pharmaceuticals and Evolutionary Genomics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acumen Pharmaceuticals position performs unexpectedly, Evolutionary Genomics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evolutionary Genomics will offset losses from the drop in Evolutionary Genomics' long position.

The idea behind Acumen Pharmaceuticals and Evolutionary Genomics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.